Anbio Biotechnology
Anbio Biotechnology (NNNN): ~8 mo cash runway. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
7.7 months
D/E 0.00
N/A
N/A
N/A
N/A
A transparent, data-derived signal for Anbio Biotechnologyacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$696.1M
Cash
$7.8M
Quarterly Burn
$6.7M
Runway
7.7 mo
Revenue
$8.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$1.4M
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 25,763 | $662K |
| eversource wealth advisors, llc | 1,696 | $317K |
| bnp paribas financial markets | 10,400 | $267K |
| morgan stanley | 7,338 | $189K |
| wells fargo & company/mn | 100 | $3K |
Frequently asked questions
What is Anbio Biotechnology's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Anbio Biotechnology has approximately 7.7 months of cash runway.
What is Anbio Biotechnology's market capitalization?
Anbio Biotechnology's market capitalization is approximately $696.1M.
Who is the CEO of Anbio Biotechnology?
Mr. Michael Lau M.B.A., Ph.D. is the chief executive officer of Anbio Biotechnology (NNNN).
Get the full picture on Anbio Biotechnology
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.